01 RSV Mat Peds Chu 508
Document text
Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group Helen Chu, MD, MPH Chair, Maternal/Pediatric RSV Work Group ACIP Meeting October 23, 2024 1U.S. Centers for Disease Control and Prevention All infants should be protected against severe RSV disease with either maternal RSV vaccine or nirsevimab Maternal vaccine Abrysvo , Pfizer *Either maternal RSV vaccine or nirsevimab is given to protect infants against severe RSV disease – only one is needed in most instances Pregnant persons 32 through 36 weeks’ gestation Administer September through January in most of thecontinental United States†All infants <8 months* Second season dose for children ages 8 –19 months at increased risk of severe RSV disease Administer October through March in most of the continental United States † (earlier the better) † Timing of administration for RSV immunization may differ in jurisdictions with RSV seasonality that differs from most of the continental United StatesNirsevimab Beyfortus , Sanofi & AstraZeneca Nirsevimab and maternal vaccination have different administration windows to provide optimal protection to the infant Forinfants born shortly before October, or during October through March who are not protected by maternal RSV vaccine, immunize within 1 week of birth, ideally during the birth hospitalization •Safety and efficacy of clesrovimab — Dr. Anushua Sinha (Merck) •Maternal RSV vaccine safety — Dr. Malini B. DeSilva (Health Partners Institute) •Work Group considerations — Ms. Danielle Moulia (CDC/NCIRD)Agenda 4 Work group members (external) ACIP Members Helen Chu (chair) Oliver Brooks Denise JamiesonConsultants Cody Meissner (Dartmouth Geisel School of Medicine) Daniel Feikin (World Health Organization) Kevin Ault (Western Michigan University) Pablo Sanchez (Nationwide Children’s Hospital) Liaisons James McAuley (IDSA) Brenna Hughes (ACOG) Nicole Chaisson (AAFP) Sean O’Leary (AAP) Jennifer Schuster (PIDS) Molly Howell (AIM) Dana DeShon (NAPNAP)GRADE/ EtRConsultants Doug Campos -Outcalt Rebecca MorganEx Officio Members Lucia Lee (FDA -CBER) Yodit Belew (FDA -CDER) Prabha Viswanathan (FDA -CDER) Yugenia Hong -Nguyen (FDA -CDER) Sonnie Kim (NIH -NIAID) April Killikelly (Public Health Agency of Canada) Elissa Abrams (Public Health Agency of Canada) Jessica Lee (CMS/CMCS) Terry Dalle -Tezze (HRSA) Matthew Clark (IHS) 5 Work group members (CDC) Tami Skoff Angie Campbell Michael Melgar Amadea Britton Amanda Payne Noelle Molinari Fiona Havers Pragna PatelRuth Link -Gelles Monica Godfrey Heidi Moline Hannah Rosenblum Manisha Patel Heather Scobie Michele Hlavsa CDC ACIP Staff Melinda Wharton Stephanie Thomas Jessica MacNeilMonica Patton Jarrett Gartin Dennis Wang Jordan Singleton Trang Nguyen Wisard Fatimah Dawood Agustin Lopez Lakshmi PanagiotakopoulosCDC Jefferson Jones (co -lead) Danielle Moulia (co -lead) Katherine Fleming -Dutra Meredith McMorrow Mila Prill Natalie Thornburg Aron Hall Ismael Ortega -Sanchez Melissa Coughlin Jamison Pike Lauren RoperA. Patricia Wodi Christine Olson Anne Hause Andrew Leidner David Shay Sarah Meyer Pedro Moro Tarayn Fairlie John Su Micheal McNeal Julianne Gee Naomi Tepper 6 For more information, contact CDC 1-800-CDC-INFO (232 -4636) TTY: 1 -888-232-6348 cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention. Thank you